Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 221


Targeting Fluorescent Nanodiamonds to Vascular Endothelial Growth Factor Receptors in Tumor.

Torelli MD, Rickard AG, Backer MV, Filonov DS, Nunn NA, Kinev AV, Backer JM, Palmer GM, Shenderova OA.

Bioconjug Chem. 2019 Mar 20;30(3):604-613. doi: 10.1021/acs.bioconjchem.8b00803. Epub 2019 Jan 31.


Do coaching style and game circumstances predict athletes' perceived justice of their coach? A longitudinal study in elite handball and volleyball teams.

De Backer M, Reynders B, Boen F, Van Puyenbroeck S, Vande Broek G.

PLoS One. 2018 Oct 15;13(10):e0205559. doi: 10.1371/journal.pone.0205559. eCollection 2018.


Pair Distribution Function Analysis of ZrO₂ Nanocrystals and Insights in the Formation of ZrO₂-YBa₂Cu₃O₇ Nanocomposites.

Rijckaert H, De Roo J, Van Zele M, Banerjee S, Huhtinen H, Paturi P, Bennewitz J, Billinge SJL, Bäcker M, De Buysser K, Van Driessche I.

Materials (Basel). 2018 Jun 23;11(7). pii: E1066. doi: 10.3390/ma11071066.


Imaging VEGF Receptors and αvβ3 Integrins in a Mouse Hindlimb Ischemia Model of Peripheral Arterial Disease.

Tekabe Y, Li Q, Zhang G, Johnson J, Schmidt AM, Backer M, Backer J, Johnson LL.

Mol Imaging Biol. 2018 Dec;20(6):963-972. doi: 10.1007/s11307-018-1191-1.


Safety and tolerability of lacosamide monotherapy in the elderly: A subgroup analysis from lacosamide trials in diabetic neuropathic pain.

Bainbridge J, De Backer M, Eckhardt K, Tennigkeit F, Bongardt S, Sen D, Werhahn KJ, Shaibani A, Faught E.

Epilepsia Open. 2017 Sep 11;2(4):415-423. doi: 10.1002/epi4.12079. eCollection 2017 Dec.


Lacosamide monotherapy in clinical practice: A retrospective chart review.

Villanueva V, Giráldez BG, Toledo M, De Haan GJ, Cumbo E, Gambardella A, De Backer M, Joeres L, Brunnert M, Dedeken P, Serratosa J.

Acta Neurol Scand. 2018 Sep;138(3):186-194. doi: 10.1111/ane.12920. Epub 2018 Mar 14.


Adjunctive lacosamide for focal epilepsy: an open-label trial evaluating the impact of flexible titration and dosing on safety and seizure outcomes.

Baulac M, Coulbaut S, Doty P, McShea C, De Backer M, Bartolomei F, Vlaicu M.

Epileptic Disord. 2017 Jun 1;19(2):186-194. doi: 10.1684/epd.2017.0907.


Selective Imaging of Vascular Endothelial Growth Factor Receptor-1 and Receptor-2 in Atherosclerotic Lesions in Diabetic and Non-diabetic ApoE-/- Mice.

Tekabe Y, Johnson LL, Rodriquez K, Li Q, Backer M, Backer JM.

Mol Imaging Biol. 2018 Feb;20(1):85-93. doi: 10.1007/s11307-017-1045-2.


Rapid Imaging of Tumor Cell Death In Vivo Using the C2A Domain of Synaptotagmin-I.

Neves AA, Xie B, Fawcett S, Alam IS, Witney TH, de Backer MM, Summers J, Hughes W, McGuire S, Soloviev D, Miller J, Howat WJ, Hu DE, Rodrigues TB, Lewis DY, Brindle KM.

J Nucl Med. 2017 Jun;58(6):881-887. doi: 10.2967/jnumed.116.183004. Epub 2017 Feb 16.


Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.

Baulac M, Rosenow F, Toledo M, Terada K, Li T, De Backer M, Werhahn KJ, Brock M.

Lancet Neurol. 2017 Jan;16(1):43-54. doi: 10.1016/S1474-4422(16)30292-7. Epub 2016 Nov 24. Erratum in: Lancet Neurol. 2017 Feb;16(2):102.


Bis-pyridylethenyl benzene as novel backbone for amyloid-β binding compounds.

Nabuurs RJ, Kapoerchan VV, Metaxas A, Hafith S, de Backer M, Welling MM, Jiskoot W, van den Nieuwendijk AM, Windhorst AD, Overkleeft HS, van Buchem MA, Overhand M, van der Weerd L.

Bioorg Med Chem. 2016 Dec 1;24(23):6139-6148. doi: 10.1016/j.bmc.2016.05.022. Epub 2016 May 18.


A "Dock and Lock" Approach to Preparation of Targeted Liposomes.

Backer MV, Backer JM.

Methods Mol Biol. 2017;1522:83-92.


Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.

Meyer JP, Edwards KJ, Kozlowski P, Backer MV, Backer JM, Lewis JS.

J Nucl Med. 2016 Nov;57(11):1811-1816. Epub 2016 Jul 7.


Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy.

Baulac M, Byrnes W, Williams P, Borghs S, Webster E, De Backer M, Dedeken P.

Acta Neurol Scand. 2017 Apr;135(4):434-441. doi: 10.1111/ane.12691. Epub 2016 Oct 6.


Antibiotic Therapy in the Treatment of Odontogenic Infections-An Evolving Landscape.

Weeda L Jr, Backer MJ.

J Tenn Dent Assoc. 2016 Fall;96(2):13-17. Review.


Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine.

Meador KJ, Loring DW, Boyd A, Echauz J, LaRoche S, Velez-Ruiz N, Korb P, Byrnes W, Dilley D, Borghs S, De Backer M, Story T, Dedeken P, Webster E.

Epilepsy Behav. 2016 Sep;62:267-75. doi: 10.1016/j.yebeh.2016.07.007. Epub 2016 Aug 10.


Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: A small phase IIIb, prospective, multicenter, open-label trial.

Elger CE, Rademacher M, Brandt C, Elmoufti S, Dedeken P, Eckhardt K, Tennigkeit F, De Backer M.

Epilepsy Behav. 2016 Sep;62:1-5. doi: 10.1016/j.yebeh.2016.05.023. Epub 2016 Jul 15.


A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures.

Steinhoff BJ, Eckhardt K, Doty P, De Backer M, Brunnert M, Schulze-Bonhage A.

Epilepsy Behav. 2016 May;58:35-43. doi: 10.1016/j.yebeh.2016.02.041. Epub 2016 Apr 4.


Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy.

Rusckowski M, Wang Y, Blankenberg FG, Levashova Z, Backer MV, Backer JM.

EJNMMI Res. 2016 Dec;6(1):4. doi: 10.1186/s13550-016-0163-1. Epub 2016 Jan 16.


Pediatric Fistula Initiative: Reducing Bloodstream Infections in an Outpatient Pediatric Hemodialysis Center.

Chotikanatis K, Suman N, Bäcker M, Paudyal B, Schoeneman M, Kohlhoff S, Hammerschlag MR.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):363-6. doi: 10.1093/jpids/piu053. Epub 2014 Jun 10.


Supplemental Content

Loading ...
Support Center